Expression of Vasohibin-1 and -2 Predicts Poor Prognosis Among Patients with Squamous Cell Carcinoma of the Esophagus

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Sep 26

PMID 30250596

Citations 11

Authors

Yamato Ninomiya

Soji Ozawa

Junya Oguma

Akihito Kazuno

Miho Nitta

Hiroshi Kajiwara

Yasufumi Sato

Affiliations

Soon will be listed here.

Abstract

Vasohibin (VASH) -1 and -2 are novel angiogenic regulators. The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC). A total of 209 patients with ESCC were investigated. Resected tumor specimens were immunostained using anti-CD34 antibody, anti-VASH1 antibody and anti-VASH2 antibody. The ratio of the microvessels density and the VASH1 density as the VASH1-positive ratio were defined and the patients were divided into two groups (a high VASH1 group and a low VASH1 group) according to the average value. The patients were also divided into two groups (a high VASH2 group and a low VASH2 group) according to VASH2 expression upon immunostaining. The clinical outcomes of these two groups were then evaluated. The high VASH1 group contained 106 patients (50.7%). The high VASH2 group contained 48 patients (23.0%). Long-term survival was significantly poorer in the high VASH1 group compared with that in the low VASH1 group. A slight correlation between VASH1 expression and VASH2 expression was observed. The low VASH1/low VASH2 group had a better prognosis than the other three groups with different combinations of VASH1 and VASH2 expression levels. The present study showed that high VASH1 expression and high VASH2 expression may be novel independent predictors of a poor prognosis in patients with ESCC and that a slight correlation between VASH1 and VASH2 expression existed. The present findings suggest that combined evaluation of VASH1 and VASH2 expression should provide an improved understanding of their clinicopathological features.

Citing Articles

Novel strategy of liver cancer treatment with modified antisense oligonucleotides targeting human vasohibin-2.

Horie S, Suzuki Y, Yamamoto T, Obika S, Mohri K, Kiyota C Cancer Sci. 2023; 114(9):3740-3749.

PMID: 37430466 PMC: 10475766. DOI: 10.1111/cas.15897.

A high-throughput test enables specific detection of hepatocellular carcinoma.

Cheishvili D, Wong C, Karim M, Kibria M, Jahan N, Chandra Das P Nat Commun. 2023; 14(1):3306.

PMID: 37286539 PMC: 10247794. DOI: 10.1038/s41467-023-39055-7.

Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification.

Aili Y, Maimaitiming N, Maimaiti A, Liu W, Qin H, Ji W J Oncol. 2022; 2022:2621969.

PMID: 36504559 PMC: 9729035. DOI: 10.1155/2022/2621969.

Tumor Microenvironment in Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: Interaction between Tumors and Immune Cells, and Potential Effects of Neuroendocrine Differentiation on the Tumor Microenvironment.

Tsunokake J, Fujishima F, Watanabe H, Sato I, Miura K, Sakamoto K Cancers (Basel). 2022; 14(9).

PMID: 35565281 PMC: 9100554. DOI: 10.3390/cancers14092152.

Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.

Strzelczyk J, Wojcik-Giertuga M, Cuber P, Biernacki K, Kos-Kudla B, Strzelczyk J Biomed Res Int. 2022; 2022:9084393.

PMID: 35372578 PMC: 8966743. DOI: 10.1155/2022/9084393.

References

Murakami K, Kasajima A, Kawagishi N, Sekiguchi S, Fujishima F, Watanabe M . The prognostic significance of vasohibin 1-associated angiogenesis in patients with hepatocellular carcinoma. Hum Pathol. 2014; 45(3):589-97. DOI: 10.1016/j.humpath.2013.10.028. View

Koyanagi T, Suzuki Y, Komori K, Saga Y, Matsubara S, Fujiwara H . Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment. Cancer Sci. 2016; 108(3):512-519. PMC: 5378258. DOI: 10.1111/cas.13149. View

Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y . Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. Lab Invest. 2017; 97(7):854-862. DOI: 10.1038/labinvest.2017.26. View

Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K . Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014; 105(11):1480-6. PMC: 4462379. DOI: 10.1111/cas.12525. View

Shimizu K, Watanabe K, Yamashita H, Abe M, Yoshimatsu H, Ohta H . Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Commun. 2005; 327(3):700-6. DOI: 10.1016/j.bbrc.2004.12.073. View

. Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus. 2017; 14(1):1-36. PMC: 5222932. DOI: 10.1007/s10388-016-0551-7. View

Koyanagi T, Saga Y, Takahashi Y, Suzuki Y, Suzuki M, Sato Y . Downregulation of vasohibin-2, a novel angiogenesis regulator, suppresses tumor growth by inhibiting angiogenesis in endometrial cancer cells. Oncol Lett. 2013; 5(3):1058-1062. PMC: 3576280. DOI: 10.3892/ol.2013.1119. View

Kitajima T, Toiyama Y, Tanaka K, Saigusa S, Kobayashi M, Inoue Y . Vasohibin-1 increases the malignant potential of colorectal cancer and is a biomarker of poor prognosis. Anticancer Res. 2014; 34(10):5321-9. View

Xue X, Gao W, Sun B, Xu Y, Han B, Wang F . Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 2012; 32(13):1724-34. DOI: 10.1038/onc.2012.177. View

10.

Sato Y . The vasohibin family: Novel regulators of angiogenesis. Vascul Pharmacol. 2012; 56(5-6):262-6. DOI: 10.1016/j.vph.2012.01.002. View

11.

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

12.

Roviello G, Petrioli R, Marano L, Polom K, Marrelli D, Perrella A . Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015; 19(1):31-41. DOI: 10.1007/s10120-015-0537-5. View

13.

Sato Y . Is vasohibin-1 for more than angiogenesis inhibition?. J Biochem. 2011; 149(3):229-30. DOI: 10.1093/jb/mvq152. View

14.

Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N . The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013; 108(10):2123-9. PMC: 3670477. DOI: 10.1038/bjc.2013.169. View

15.

Shih C, Ozawa S, Ando N, Ueda M, Kitajima M . Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000; 6(3):1161-8. View

16.

Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K . Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci. 2008; 100(1):88-94. PMC: 11159213. DOI: 10.1111/j.1349-7006.2008.01015.x. View

17.

. Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus. 2017; 14(1):37-65. PMC: 5222925. DOI: 10.1007/s10388-016-0556-2. View

18.

Takeuchi H, Ozawa S, Shih C, Ando N, Kitagawa Y, Ueda M . Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. Int J Cancer. 2004; 109(4):483-90. DOI: 10.1002/ijc.11734. View

19.

Nasu T, Maeshima Y, Kinomura M, Hirokoshi-Kawahara K, Tanabe K, Sugiyama H . Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes. 2009; 58(10):2365-75. PMC: 2750227. DOI: 10.2337/db08-1790. View

20.

Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T . Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 2012; 10(9):1135-46. DOI: 10.1158/1541-7786.MCR-12-0098-T. View